BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 19569249)

  • 41. Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders.
    Zhang LJ; Shin ES; Yu ZX; Li SB
    Chin Med J (Engl); 2007 Nov; 120(22):2002-5. PubMed ID: 18067786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cytogenetics of myelodysplastic syndromes].
    Laï JL; Fenaux P
    Pathol Biol (Paris); 1997 Sep; 45(7):550-5. PubMed ID: 9404478
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
    Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Morphology, cytogenetics and classification of MDS.
    Giagounidis A; Haase D
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):337-53. PubMed ID: 24507811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prospective clinical study of diagnosis and classification for 282 cases with primary myelodysplastic syndrome].
    Wang XQ;
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):546-9. PubMed ID: 17172130
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions.
    Valent P; Horny HP
    Eur J Clin Invest; 2009 Jul; 39(7):548-53. PubMed ID: 19453651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface.
    Wimazal F; Fonatsch C; Thalhammer R; Schwarzinger I; Müllauer L; Sperr WR; Bennett JM; Valent P
    Leuk Res; 2007 Nov; 31(11):1461-8. PubMed ID: 17507091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Study on the burden of abnormal hematopoietic clone of the patients with myelodysplastic syndromes and its implications].
    Wang HQ; Shao ZH; Shi J; Cao YR; Liu H; Bai J; Tu MF; Xing LM; Cui ZZ; Liu SH; Sun J; Jia HR; Yang TY
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):473-6. PubMed ID: 16383238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan.
    Moriwaki K; Manabe A; Taketani T; Kikuchi A; Nakahata T; Hayashi Y
    Int J Hematol; 2014 Nov; 100(5):478-84. PubMed ID: 25261124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes.
    Gondek LP; Haddad AS; O'Keefe CL; Tiu R; Wlodarski MW; Sekeres MA; Theil KS; Maciejewski JP
    Exp Hematol; 2007 Nov; 35(11):1728-38. PubMed ID: 17920760
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clonal chromosomal aberrations in patients with aplastic anemia at the disease onset and transformation].
    Ol'shanskaia IuV; Mikhaĭlova EA; Domracheva EV; Udovichenko AI; Davidian IuR; Vodinskaia LA; Zakharova AV; Kokhno AV; Kaplanskaia IB; Tikhonova LIu; Tsvetaeva NV; Parovichnikova EN; Savchenko VG
    Ter Arkh; 2006; 78(7):31-4, 36-7. PubMed ID: 16944748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls.
    Stachurski D; Smith BR; Pozdnyakova O; Andersen M; Xiao Z; Raza A; Woda BA; Wang SA
    Leuk Res; 2008 Feb; 32(2):215-24. PubMed ID: 17675229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monoclonal antibody panels for acute leukemia and myelodysplastic syndrome diagnosis. Results of a co-operative quality control group.
    Basso G; Bernasconi P; Chianese R; Crovetti G; Garbaccio G; Iavarone A; Pautasso M; Santagostino A; Stacchini A;
    J Biol Regul Homeost Agents; 2001; 15(2):145-55. PubMed ID: 11501972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytogenetic study of myelodysplastic syndrome from India.
    Vundinti BR; Kerketta L; Jijina F; Ghosh K
    Indian J Med Res; 2009 Aug; 130(2):155-9. PubMed ID: 19797812
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
    Bock O
    Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Vasculitis associated with a myelodysplastic syndrome: a report of 5 cases].
    Fernández-Miranda C; García-Marcilla A; Martín M; Gil R; Vanaclocha F; Torres N; del Palacio A
    Med Clin (Barc); 1994 Oct; 103(14):539-42. PubMed ID: 7799667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Flow-cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes.
    Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
    Am J Hematol; 2005 Jul; 79(3):243-5. PubMed ID: 15981222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Analysis and clinical significance of ETV6 rearrangement in myelodysplastic syndromes patients].
    Ding BT; Guo NJ; Sun JZ; Gao HM; Wang YS; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2007 Dec; 28(12):804-7. PubMed ID: 18476590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients.
    Steidl C; Steffens R; Gassmann W; Hildebrandt B; Hilgers R; Germing U; Trümper L; Haase D
    Leuk Res; 2005 Sep; 29(9):987-93. PubMed ID: 16038724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.